Crucell (CRXLY) Stock Price, News & Analysis

Crucell NV is a Netherlands-based biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. The Company’s product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. It focuses on the paediatric, travel and endemic, and respiratory fields. Its core product portfolio includes Quinvaxem, a liquid pentavalent vaccine against five important childhood diseases; Hepavax-Gene, a hepatitis B vaccine; Epaxal, an aluminum-free hepatitis A vaccine; Vivotif and Dukoral, oral vaccines against typhoid and cholera; and Inflexal V, a virosomal adjuvanted vaccine against influenza. It has offices in the Netherlands, China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States and Vietnam.